Shandong Wohua Pharmaceutical (002107.SZ) released its 1H 2024 performance forecast, with an expected net income attributable to shareholders of the listed company of...
According to the announcement by Wohua Pharmaceutical (002107.SZ) on its 1H 2024 performance forecast, the net income attributable to shareholders of the listed company is expected to be between 8.9 million yuan and 13.2 million yuan, a decrease of 64.52% - 76.08% year-on-year.
Reasons for the performance change: the company's core product, Chinese patent medicine Wohua Xin Keshu Tablets, was selected by the National Chinese Medicine Procurement Alliance for centralized quantity purchasing in June 2023, with a bid price about 39% lower than the original price. During this reporting period, Wohua Pharmaceutical implemented the centralized procurement price for its Xin Keshu Tablets, which not only caused a reduction in sales revenue, but also a decrease in gross profit contribution and an decline in operating profit.